Wikipedia

User:Strawbblue/sandbox

< User:Strawbblue

Intestinal hypoganglionosis

edit
Intestinal hypoganglionosis
Other namesHypoganglionosis, isolated hypoganglionosis
Myenteric plexus of the enteric nervous system (ENS), where ganglion cell reduction occurs in intestinal hypoganglionosis
SymptomsChronic constipation, abdominal distension, vomiting, feeding intolerance, enterocolitis
CausesReduction of ganglion cells in the myenteric plexus and interstitial cells of Cajal
Diagnostic methodFull-thickness biopsy, immunohistochemistry
TreatmentSurgical resection, enterostomy, total parenteral nutrition
PrognosisFavorable for segmental disease, poor for extensive small bowel involvement

Intestinal hypoganglionosis, also known as isolated hypoganglionosis (IH), is a rare disorder in which the intestine contains fewer ganglia (clusters of nerve cells) than normal, impairing its ability to move food through the digestive tract. The condition causes chronic constipation, abdominal swelling, and vomiting, and in severe cases can lead to complete bowel obstruction and intestinal failure.

IH may be present from birth (congenital), occurring when the enteric nervous system (ENS) –  a network of nerves that controls the digestive tract – does not fully develop before birth; alternatively, it may be acquired later in life following damage to previously normal nerve cells by viral infections, autoimmune conditions, or impaired blood flow. Unlike Hirschsprung's disease, in which the affected bowel completely lacks ganglia, IH involves only a partial reduction in the myenteric plexus, a network of nerves within the ENS that is responsible for the muscle contractions propelling digested material forward.

Because IH and Hirschsprung's share similar symptoms and imaging results, IH is frequently misdiagnosed or diagnosed late. Diagnosis requires a surgical biopsy that samples the full thickness of the intestinal wall, examined using specialised laboratory staining techniques.

There are no internationally standardised treatment guidelines for IH, though surgical removal of affected bowel segments is the primary approach. Severe disease, particularly involving the small intestine, carries a poor prognosis. Overall mortality is approximately 8%, with most deaths caused by bowel infection (enterocolitis) or complications from repeated surgery. IH accounts for 3–5% of congenital intestinal nerve disorders and is frequently diagnosed in infancy or childhood. The condition is most widely recognised in Japan, where it has been formally classified with national guidelines established. However, due to the lack of standardised international guidelines, patient care varies between institutions, requiring families to travel for treatment.

Signs and symptoms

edit
Severe abdominal distension, a common presenting feature of hypoganglionosis
Severe abdominal distension, a common feature of IH

IH causes a wide range of symptoms that primarily affect the gastrointestinal tract, though severe or prolonged disease can involve the liver, kidneys, and cardiovascular system.[1]

Gastrointestinal

edit

Gastrointestinal symptoms of IH include chronic constipation, abdominal distension, abdominal pain, and vomiting. In newborns, bowel obstruction typically presents within the first days of life, with bile-stained vomiting, progressive abdominal distension (swelling), and feeding intolerance.[2][3] Unlike Hirschsprung's disease, failure to pass the first stool (meconium) is not a consistent symptom of IH in the newborn period.[4] In older children and adults, the predominant symptoms are bowel obstruction and severe refractory constipation.[5] Recurrent enterocolitis, also a common complication, is a leading cause of death in severe disease.[4]

Bag for intravenous delivery of TPN

Hepatic

edit

In patients with IH, feeding intolerance often leads to dependence on total parenteral nutrition (TPN), a method of supplying nutrition directly into the bloodstream via an intravenous line. Prolonged TPN use, combined with sepsis and reduced bile flow, can cause intestinal failure-associated liver disease (IFALD).[6] Newborns and infants with IH are particularly vulnerable to severe and progressive IFALD.[7] Central line infections, which frequently occur in TPN-dependent patients, can further accelerate liver injury.[6]

Systemic

edit

Limited evidence suggests that severe dilatation of the large intestine in IH – most commonly involving the sigmoid colon and rectum – can cause a dangerous rise in abdominal pressure, known as abdominal compartment syndrome (ACS). Affecting multiple organ systems, including the lung and kidneys, this life-threatening complication may also lead to focal ischaemia (impaired blood flow) of the colon wall.[8]

Causes

edit

Congenital hypoganglionosis (C-IH)

edit

C-IH is a developmental disorder arising from the incomplete development or migration of nerve cells during fetal development (embryogenesis).[9][10] During normal ENS development, the glial cell line-derived neurotrophic factor (GDNF) signaling pathway plays a central role in guiding young nerve cells to migrate into the gut wall. Mutations disrupting the pathway may therefore result in fewer ganglion cells reaching the ENS. However, no single consistent genetic cause has been identified.[2]

Acquired hypoganglionosis (A-IH)

edit

A-IH develops after birth as a result of damage to the ganglia, rather than a congenital abnormality. This may follow an injury to the bowel that deprives the tissues of oxygen, such as ischaemia from a severe intestinal blockage, twisting of the bowel (volvulus), or surgical complications.[8][11] Other triggers reported in case studies include bacterial or viral infections and immune-related conditions in which inflammation may damage the ENS.[8][12] A report has also linked chronic inflammatory conditions, such as ulcerative colitis and Crohn's disease, to IH.[13]

Pathophysiology

edit

IH is associated with disruption of three systems responsible for normal bowel motility: the enteric nervous system (ENS), the intestinal smooth muscle, and pacemaker cells called interstitial cells of Cajal (ICCs).[14][15]

Ganglion cells in the myenteric plexus, which are reduced in IH

Enteric nervous system (ENS)

edit

The ENS regulates intestinal movement through two networks of ganglion cells in the gut wall: the myenteric plexus, which controls muscle contractions along the bowel, and the submucosal plexus, which regulates secretion and local blood flow.[16] In IH, the number of ganglia in the myenteric plexus is significantly reduced, while those in the submucosal plexus remain intact.[9] The nerve cells present are often abnormally small and immature, weakening muscle contractions that propel intestinal contents forward – leading to bowel obstruction and constipation.[11][17]

Beyond the reduction in ganglion cells, the remaining nerve fibers in the gut wall also exhibit abnormalities. These include reduced expression of neural cell adhesion molecules (NCAM) – a protein that identifies healthy nerve cells – within the gut wall, suggesting the remaining nerves are not fully functional.[1] Decreased activity of acetylcholinesterase, a nerve-related enzyme, is also found in the connective tissue beneath the intestinal lining (lamina propria).[4]

Unlike Hirschsprung's disease, where ganglion cells are entirely absent, IH involves a reduction rather than a complete loss of the cells.[5] The distribution of this reduction is uneven, meaning some segments of bowel may appear near-normal while others are severely affected.[18]

Intestinal smooth muscles

edit
ICCs drive smooth muscle contraction and receive input from enteric neurons (blue); in hypoganglionosis, ICC density is reduced

When the bowel wall does not receive sufficient nerve signals in IH, the surrounding muscle layers may undergo structural changes in response, such as the thickening of the muscle lining.[13] Changes in nerve fibre distribution within the muscle have also been observed, which may arise from the bowel wall adapting to long-term under-innervation.[19]

Interstitial cells of Cajal (ICCs)

edit

In individuals with IH, the number of ICCs is reduced in nearly all segments of the affected intestine, including around the myenteric plexus and within the smooth muscle layers.[5] ICCs act as the pacemakers of the gut, generating electrical signals that drive intestinal smooth muscle contractions.[20] Therefore, the reduction in ICC may directly contribute to the contraction problems seen in IH – even in bowel segments where ganglion cells are still present – though the precise relationship between ICC loss and ganglion cell reduction is still unclear.[21]

Diagnosis

edit

IH is difficult to distinguish from Hirschsprung's disease due to similar symptoms and imaging.[3] Definitive diagnosis of IH requires a full-thickness intestinal biopsy to confirm three hallmarks of the disease: very low activity of acetylcholinesterase (AChE), significant reduction of ganglia in the myenteric plexuses, and thickening of smooth muscle layers (muscularis mucosae).[22] Unlike the smaller samples used to diagnose Hirschsprung's, IH requires larger surgical specimens – at minimum 1 cm in length and covering two-thirds of the bowel's circumference – making standard rectal suction biopsies insufficient because they do not adequately sample the myenteric plexus.[3][5][23]

Histology of intestinal smooth muscle, which thickens in IH

Immunohistochemistry

edit

Histological diagnosis (microscopic examination of tissue) is performed with the S100 antibody, which highlights the myenteric plexus in the ENS, revealing the significantly reduced area occupied by ganglia in IH. Staining with alpha smooth muscle actin (alpha-SMA) may show the thickening of the circular and longitudinal muscle.[3][5]

Differential diagnosis

edit

No international consensus exists on the diagnostic criteria for IH, and establishing a diagnosis remains difficult; however, radiology findings can closely mimic those of Hirschsprung's disease, which further complicates the diagnostic process.[1][2] Differentiating the two conditions is possible through AChE staining, which is positive in Hirschsprung's but negative in IH.[2][18] Radiologically, Hirschsprung's typically shows a clear transition zone between the narrowed and dilated bowel, whereas in IH this transition is less clearly defined.[24] Only 32% of IH cases were diagnosed during the newborn period, and sampling errors may lead to delayed diagnosis and repeated hospitalisation.[4]

Treatment

edit

Surgery

edit
A vial of Omegaven used to treat liver disease in patients receiving total parenteral nutrition
A vial of fish oil triglycerides (Omegaven) for individuals receiving TPN

Surgery is the primary treatment for bowel obstruction caused by IH. The most common approach is a removal of the affected segment (resection).[6] In many newborns, however, reconnection surgery (primary anastomosis) is not feasible due to bowel dilatation or instability. In these cases, a temporary opening (stoma) is created to decompress the bowel and allow intestinal growth before the procedure.[3] For IH, a jejunostomy, a stoma in the upper small intestine, is recommended, as it leads to better survival and fewer blockages than other types of ostomies, such as an ileostomy or colostomy.[9][25]

Medical management

edit

Drugs that stimulate the bowel (prokinetics) and corticosteroids have been trialed but have not shown significant long-term clinical benefit. Consequently, no medication is currently recommended for IH.[25] For infants with IH-related intestinal failure, long-term total parenteral nutrition (TPN) is often necessary. In these cases, a fish-oil based omega−3 fatty acid emulsion (Omegaven) has been reported to improve liver function. In severe C-IH where TPN cannot be discontinued, small intestinal transplantation may be considered.[25][26]

Prognosis

edit

The prognosis of IH varies depending on the extent of bowel involvement and age of onset. Individuals with segmental disease generally have favourable outcomes following surgical resection; in contrast, C-IH involving the small intestine carries a poor long-term prognosis.[4] Most individuals remain dependent on TPN and enterostomy, and bowel function often remains poor despite improved survival.[3] Overall mortality is approximately 8%, with most deaths occurring due to enterocolitis or short bowel syndrome after repeated surgery.[4]

Epidemiology

edit

IH is among the rarest intestinal innervation disorders, accounting for 3–5% of congenital intestinal nerve disorders.[4] As it is difficult to distinguish from Hirschsprung's disease without full-thickness biopsies, its true incidence is likely underreported.[5][6] However, the disease is most frequently recognised in Japan, where specific protocols for identifying and treating "allied disorders of Hirschsprung's disease" have been established.[25][27]

The condition primarily presents in childhood with a median diagnosis age of 4.85 years, though symptoms frequently emerge in the neonatal period (first 28 days of life).[3][4] Adult-onset types are extremely rare and typically identified in individuals who have a history of refractory constipation that worsens in their 30s or 40s.[9][13] Sex distribution varies by region: while some global systematic reviews suggest a male predominance of 3:1, a higher frequency in females has been reported in a Japanese survey, which found a male-to-female ratio of approximately 1:1.6.[4][27]

Society and culture

edit
An ostomy bag used to collect waste

Awareness and advocacy

edit

Due to its rarity, IH is often grouped with Hirschsprung's disease in medical literature and patient advocacy.[2] The lack of standardised international guidelines means that patient care varies between institutions, which may require families to travel to specialised centres for treatment.[5]

Impact on quality of life

edit

For individuals with severe IH, the condition is chronic and may require long-term treatment. Living with a permanent or temporary stoma can lead to social anxiety and body image concerns, particularly in children and young adults.[28] In some cases, treatments like fish-oil-based triglycerides are only available through expanded access programs, creating regulatory hurdles for those seeking novel therapies.[6]

References

edit
  1. 1 2 3 Friedmacher, Florian; Puri, Prem (2013-09-01). "Classification and diagnostic criteria of variants of Hirschsprung's disease". Pediatric Surgery International. 29 (9): 855–872. doi:10.1007/s00383-013-3351-3. ISSN 1437-9813.
  2. 1 2 3 4 5 Sreedher, Gayathri; Garrison, Aaron; Novak, Robert; Keisling, Matthew; Ganapathy, Shankar Srinivas (February 2019). "Congenital intestinal hypoganglionosis: A radiologic mimic of Hirschsprung's disease". Radiology Case Reports. 14 (2): 171–174. doi:10.1016/j.radcr.2018.10.007. ISSN 1930-0433. PMC 6222261. PMID 30416639.
  3. 1 2 3 4 5 6 7 Yamada, Yohei; Mori, Teizaburo; Takahashi, Nobuhiro; Fujimura, Takumi; Kano, Motohiro; Kato, Mototoshi; Takahashi, Masataka; Shimojima, Naoki; Watanabe, Toshihiko; Yoshioka, Takako; Kanamori, Yutaka; Kuroda, Tatsuo; Fujino, Akihiro (2023-10-23). "Historical Cohort Study of Congenital Isolated Hypoganglionosis of the Intestine: Determining the Best Surgical Interventions". Biomolecules. 13 (10): 1560. doi:10.3390/biom13101560. ISSN 2218-273X.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  4. 1 2 3 4 5 6 7 8 9 Dingemann, Jens; Puri, Prem (2010-08-19). "Isolated hypoganglionosis: systematic review of a rare intestinal innervation defect". Pediatric Surgery International. 26 (11): 1111–1115. doi:10.1007/s00383-010-2693-3. ISSN 0179-0358.
  5. 1 2 3 4 5 6 7 Alatas, Fatima Safira; Masumoto, Kouji; Nagata, Kouji; Pudjiadi, Antonius Hocky; Kadim, Muzal; Taguchi, Tomoaki; Tajiri, Tatsuro (2023-06-30). "Diagnostic challenges of hypoganglionosis based on immunohistochemical method". Translational Pediatrics. 12 (6): 1161169–1161169. doi:10.21037/tp-22-592. ISSN 2224-4344.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  6. 1 2 3 4 5 Khalaf, Racha; Karjoo, Sara; Danielson, Paul; Wilsey, Michael; Shakeel, Fauzia (2017). "Intestinal Hypoganglionosis Leading to Intestinal Failure and the Compassionate Use of Omegaven™". Pediatric Gastroenterology, Hepatology & Nutrition. 20 (1): 55. doi:10.5223/pghn.2017.20.1.55. ISSN 2234-8646.
  7. ↑ Venick, Robert S.; Calkins, Kara (June 2011). "The impact of intravenous fish oil emulsions on pediatric intestinal failure-associated liver disease". Current Opinion in Organ Transplantation. 16 (3): 306–311. doi:10.1097/MOT.0b013e32834670eb. ISSN 1531-7013. PMID 21505340.
  8. 1 2 3 Bergeron, Eric; Gologan, Adrian (2025-11-26). "Abdominal compartment syndrome with colonic hypoganglionosis and massive colonic distension in a young adult: A case report". World Journal of Clinical Cases. 13 (33): 112684. doi:10.12998/wjcc.v13.i33.112684. ISSN 2307-8960. PMC 12678952. PMID 41356083.{{cite journal}}: CS1 maint: article number as page number (link) CS1 maint: unflagged free DOI (link)
  9. 1 2 3 4 Huan, Pham Duc; Lieu, Dau Quang; Dung, Tran Ngoc; Long, Tran Bao; Anh, Tran Ngoc; Dung, Luu Quang; Phan, Nguyen Duc; Vinh, Nguyen-Thi Thu; Duc, Nguyen Minh (June 2023). "A case report of segmental hypoganlionosis of the ileum in an adult". Radiology Case Reports. 18 (6): 2073–2077. doi:10.1016/j.radcr.2023.03.012. ISSN 1930-0433.
  10. ↑ Lake, Jonathan I.; Heuckeroth, Robert O. (2013-07-01). "Enteric nervous system development: migration, differentiation, and disease". American Journal of Physiology. Gastrointestinal and Liver Physiology. 305 (1): G1–24. doi:10.1152/ajpgi.00452.2012. ISSN 1522-1547. PMC 3725693. PMID 23639815.
  11. 1 2 Taguchi, Tomoaki; Masumoto, Kouji; Ieiri, Satoshi; Nakatsuji, Takanori; Akiyoshi, Junko (December 2006). "New classification of hypoganglionosis: congenital and acquired hypoganglionosis". Journal of Pediatric Surgery. 41 (12): 2046–2051. doi:10.1016/j.jpedsurg.2006.08.004. ISSN 0022-3468.
  12. ↑ Besnard, M.; Faure, C.; Fromont-Hankard, G.; Ansart-Pirenne, H.; Peuchmaur, M.; Cezard, J. P.; Navarro, J. (January 2000). "Intestinal pseudo-obstruction and acute pandysautonomia associated with Epstein-Barr virus infection". The American Journal of Gastroenterology. 95 (1): 280–284. doi:10.1111/j.1572-0241.2000.01709.x. ISSN 0002-9270. PMID 10638598.
  13. 1 2 3 Kwok, Allan MF; Still, Andrew B; Hart, Kimberly (2019-02-27). "Acquired segmental colonic hypoganglionosis in an adult Caucasian male: A case report". World Journal of Gastrointestinal Surgery. 11 (2): 101–111. doi:10.4240/wjgs.v11.i2.101. ISSN 1948-9366.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  14. ↑ Obermayr, Florian; Hotta, Ryo; Enomoto, Hideki; Young, Heather M. (January 2013). "Development and developmental disorders of the enteric nervous system". Nature Reviews Gastroenterology & Hepatology. 10 (1): 43–57. doi:10.1038/nrgastro.2012.234. ISSN 1759-5053.
  15. ↑ Kobayashi, Hiroyuki; Yamataka, Atsuyuki; Lane, Geoffrey J.; Miyano, Takeshi (February 2002). "Pathophysiology of hypoganglionosis". Journal of Pediatric Gastroenterology and Nutrition. 34 (2): 231–235. doi:10.1097/00005176-200202000-00025. ISSN 0277-2116. PMID 11840047.
  16. ↑ Sharkey, Keith A.; Mawe, Gary M. (2023-04-01). "The enteric nervous system". Physiological Reviews. 103 (2): 1487–1564. doi:10.1152/physrev.00018.2022. ISSN 1522-1210. PMC 9970663. PMID 36521049.
  17. ↑ Kapur, Raj P.; Bellizzi, Andrew M.; Bond, Steffan; Chen, Haiying; Han, Jeong S.; LeGallo, Robin D.; Midgen, Craig; Poulin, Alysa A.; Uddin, Naseem; Warren, Mikako; Velázquez Vega, José E.; Zuppan, Craig W. (2021-01-22). "Congenital Myenteric Hypoganglionosis". American Journal of Surgical Pathology. 45 (8): 1047–1060. doi:10.1097/pas.0000000000001670. ISSN 0147-5185.
  18. 1 2 Schärli, A. F.; Sossai, R. (1998-08-01). "Hypoganglionosis". Seminars in Pediatric Surgery. 7 (3): 187–191. doi:10.1016/S1055-8586(98)70016-2. ISSN 1055-8586.
  19. ↑ den Braber-Ymker, Marjanne; Lammens, Martin; van Putten, Michel J. A. M.; Nagtegaal, Iris D. (February 2017). "The enteric nervous system and the musculature of the colon are altered in patients with spina bifida and spinal cord injury". Virchows Archiv: An International Journal of Pathology. 470 (2): 175–184. doi:10.1007/s00428-016-2060-4. ISSN 1432-2307. PMC 5306076. PMID 28062917.
  20. ↑ Al-Shboul, Othman A. (2013). "The importance of interstitial cells of cajal in the gastrointestinal tract". Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association. 19 (1): 3–15. doi:10.4103/1319-3767.105909. ISSN 1998-4049. PMC 3603487. PMID 23319032.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  21. ↑ Yamataka, Atsuyuki; Ohshiro, Kiyohiko; Kobayashi, Hiroyuki; Fujiwara, Toshio; Sunagawa, Masakatsu; Miyano, Takeshi (July 1997). "Intestinal pacemaker C-KIT+ cells and synapses in allied Hirschsprung's disorders". Journal of Pediatric Surgery. 32 (7): 1069–1074. doi:10.1016/s0022-3468(97)90401-2. ISSN 0022-3468.
  22. ↑ Borchard, F.; Meier-Ruge, W.; Wiebecke, B.; Briner, J.; Müntefering, H.; Födisch, H. F.; Holschneider, A. M.; Schmidt, A.; Enck, P.; Stolte, M. (May 1991). "[Disorders of the innervation of the large intestine--classification and diagnosis. Results of a consensus conference of the Society of Gastroenteropathology 1 December 1990 in Frankfurt/Main]". Der Pathologe. 12 (3): 171–174. ISSN 0172-8113. PMID 1876586.
  23. ↑ Schäppi, M. G.; Staiano, A.; Milla, P. J.; Smith, V. V.; Dias, J. A.; Heuschkel, R.; Husby, S.; Mearin, M. L.; Papadopoulou, A.; Ruemmele, F. M.; Vandenplas, Yvan; Koletzko, S. (November 2013). "A practical guide for the diagnosis of primary enteric nervous system disorders". Journal of Pediatric Gastroenterology and Nutrition. 57 (5): 677–686. doi:10.1097/MPG.0b013e3182a8bb50. ISSN 1536-4801. PMID 24177787.
  24. ↑ Kim, Hye Jin; Kim, Ah Young; Lee, Choong Wook; Yu, Chang Sik; Kim, Jung-Sun; Kim, Pyo Nyun; Lee, Moon-Gyu; Ha, Hyun Kwon (May 2008). "Hirschsprung Disease and Hypoganglionosis in Adults: Radiologic Findings and Differentiation". Radiology. 247 (2): 428–434. doi:10.1148/radiol.2472070182. ISSN 0033-8419.
  25. 1 2 3 4 Muto, Mitsuru; Matsufuji, Hiroshi; Taguchi, Tomoaki; Tomomasa, Takeshi; Nio, Masaki; Tamai, Hiroshi; Tamura, Masanori; Sago, Haruhiko; Toki, Akira; Nosaka, Shunsuke; Kuroda, Tatsuo; Yoshida, Masahiro; Nakajima, Atsushi; Kobayashi, Hiroyuki; Sou, Hideki (May 2018). "Japanese clinical practice guidelines for allied disorders of Hirschsprung's disease, 2017". Pediatrics International: Official Journal of the Japan Pediatric Society. 60 (5): 400–410. doi:10.1111/ped.13559. ISSN 1442-200X. PMID 29878629.
  26. ↑ Park, Hye Won; Lee, Na Mi; Kim, Ji Hee; Kim, Kyo Sun; Kim, Soo-Nyung (February 2015). "Parenteral fish oil-containing lipid emulsions may reverse parenteral nutrition-associated cholestasis in neonates: a systematic review and meta-analysis". The Journal of Nutrition. 145 (2): 277–283. doi:10.3945/jn.114.204974. ISSN 1541-6100. PMID 25644348.
  27. 1 2 Watanabe, Yoshio; Kanamori, Yutaka; Uchida, Keiichi; Taguchi, Tomoaki (2013-08-22). "Isolated hypoganglionosis: results of a nationwide survey in Japan". Pediatric Surgery International. 29 (11): 1127–1130. doi:10.1007/s00383-013-3378-5. ISSN 0179-0358.
  28. ↑ Ayaz-Alkaya, Sultan (February 2019). "Overview of psychosocial problems in individuals with stoma: A review of literature". International Wound Journal. 16 (1): 243–249. doi:10.1111/iwj.13018. ISSN 1742-481X. PMC 7948730. PMID 30392194.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Strawbblue/sandbox&oldid=1348622023"